Clinical trials in recurrent ovarian cancer
…, D Katsaros, JW Kim, B Miller, D Provencher… - International Journal of …, 2011 - ijgc.bmj.com
The 4th Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup was
held in Vancouver, Canada, in June 2010. Representatives of 23 cooperative research …
held in Vancouver, Canada, in June 2010. Representatives of 23 cooperative research …
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled …
…, L Elit, P Ghatage, AM Oza, M Plante, D Provencher… - The Lancet, 2017 - thelancet.com
Background Rucaparib, a poly (ADP-ribose) polymerase inhibitor, has anticancer activity in
recurrent ovarian carcinoma harbouring a BRCA mutation or high percentage of genome …
recurrent ovarian carcinoma harbouring a BRCA mutation or high percentage of genome …
[HTML][HTML] ARID1A Mutations in Endometriosis-Associated Ovarian Carcinomas
…, L Galletta, PN Tonin, D Provencher… - … England Journal of …, 2010 - Mass Medical Soc
Background Ovarian clear-cell and endometrioid carcinomas may arise from endometriosis,
but the molecular events involved in this transformation have not been described. Methods …
but the molecular events involved in this transformation have not been described. Methods …
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind …
…, M Rodrigues, JP Lotz, D Provencher… - The lancet …, 2017 - thelancet.com
Background Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, has previously
shown efficacy in a phase 2 study when given in capsule formulation to all-comer patients …
shown efficacy in a phase 2 study when given in capsule formulation to all-comer patients …
Uterine serous carcinoma
…, MM Vaughan, M Bini, M Takano, D Provencher… - Gynecologic …, 2021 - Elsevier
Serous endometrial cancer represents a relative rare entity accounting for about 10% of all
diagnosed endometrial cancer, but it is responsible for 40% of endometrial cancer-related …
diagnosed endometrial cancer, but it is responsible for 40% of endometrial cancer-related …
Gynecologic Cancer InterGroup (GCIG) consensus review for small cell carcinoma of the cervix
T Satoh, Y Takei, I Treilleux… - International Journal of …, 2014 - ijgc.bmj.com
Small cell carcinoma of the cervix (SCCC) is a rare histological entity of uterine cervical
cancer. Compared with other common histological types, squamous cell carcinoma or …
cancer. Compared with other common histological types, squamous cell carcinoma or …
[HTML][HTML] Mutation of FOXL2 in Granulosa-Cell Tumors of the Ovary
…, C Crane, J Madore, D Provencher… - … England Journal of …, 2009 - Mass Medical Soc
Background Granulosa-cell tumors (GCTs) are the most common type of malignant ovarian
sex cord–stromal tumor (SCST). The pathogenesis of these tumors is unknown. Moreover …
sex cord–stromal tumor (SCST). The pathogenesis of these tumors is unknown. Moreover …
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis …
…, JP Lotz, F Selle, I Ray-Coquard, D Provencher… - The Lancet …, 2021 - thelancet.com
Background Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, has previously
been shown to extend progression-free survival versus placebo when given to patients with …
been shown to extend progression-free survival versus placebo when given to patients with …
2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus …
…, S Pecorelli, J Pfisterer, A Poveda, D Provencher… - Annals of oncology, 2005 - Elsevier
Gynecological Cancer Intergroup (GCIG) and its member organizations: 1AGO-OVAR
(Germany), 2ANZGOG (Australia–New Zealand), 4EORTC (Europe), 6GEICO (Spain) …
(Germany), 2ANZGOG (Australia–New Zealand), 4EORTC (Europe), 6GEICO (Spain) …
[HTML][HTML] Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label …
…, G Wilson, S Brooks, S Carinelli, D Provencher… - The lancet …, 2018 - thelancet.com
Background Although women with endometrial cancer generally have a favourable
prognosis, those with high-risk disease features are at increased risk of recurrence. The …
prognosis, those with high-risk disease features are at increased risk of recurrence. The …